-
公开(公告)号：EP0308936B1
公开(公告)日：1994-07-06
申请号：EP88115607.9
申请日：1988-09-22
IPC分类号： A61K39/395 , A61K35/14 , A61K37/66
CPC分类号： C07K16/468 , A61K38/00 , A61K39/42 , C07K16/1063 , C07K16/2809 , C07K16/283 , A61K2300/00
-
公开(公告)号：EP0555880A3
公开(公告)日：1994-05-11
申请号：EP93102279.2
申请日：1993-02-12
申请人： Bristol-Myers Squibb Company , TRUSTEES OF DARTMOUTH COLLEGE , THE GENERAL HOSPITAL CORPORATION
IPC分类号： C07K15/00 , C12P21/08 , A61K37/02 , A61K39/395
CPC分类号： C07K16/2875 , A61K38/00 , A61K2039/505 , C07K14/70575 , C07K2317/73 , C07K2317/76 , Y10S514/885 , Y10S530/866 , Y10S530/868
摘要： The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusion protein was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease.
-
公开(公告)号：EP0585943A2
公开(公告)日：1994-03-09
申请号：EP93114153.5
申请日：1993-09-03
CPC分类号： C07K14/70575 , A61K38/00 , C07K14/70517 , C07K14/7056 , C07K16/2878 , C07K2317/73
摘要： The present invention relates to soluble ligands for the B-cell antigen, CD40, and, in particular, to human gp39 protein and soluble ligands derived therefrom which may be used in methods of promoting B-cell proliferation.
摘要翻译： 本发明涉及可用于促进B细胞增殖的方法中的B细胞抗原的可溶性配体，CD40，特别是涉及人gp39蛋白质及其衍生的可溶性配体。
-
-
搜索结果
33 条记录 (耗时 0.014 秒)
